VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Technical Scanner
RSI, Moving averages & volume momentum signals
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
Minervini — VCPContraction bases in Stage 2 uptrends
Minervini — Trend TemplateFull 8-rule Stage 2 screen
O'Neil — Cup with HandleBase breakouts with RS leadership
O'Neil — CANSLIM LeadersGrowth leaders with RS ≥ 85
Qullamaggie — High Tight FlagsPower plays after a large advance
Qullamaggie — Momentum Leaders1/3/6-month strength leaders
Livermore — Pivotal PointsMulti-touch resistance breakouts
View All Playbooks...
Breakouts
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
Breakouts
WatchlistPricing
Ctrl K
Pricing
PFE
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsCompareWatchlist
PFEPfizer Inc.
$27.93$159.2B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksPFEP/E History

PFE logoPfizer Inc. (PFE) P/E Ratio History

Fairly Valued

Trading at 20.5x, near 5Y avg of 19.8x · 80th percentile · In line with own history · Data 1990–2026

Current P/E (TTM)
20.5x
+4% vs 5Y avg
5Y Avg P/E
19.8x
Median 17.3x
5Y Percentile
80th
Upper end of range
PEG Ratio
N/A
5-Year P/E Range
20.5x
Min8.0xMedian17.3xMax81.1x
TTM EPS$0.76
Price$27.93
Earnings Yield4.87%
EPS Growth (1Y)-3.5%
EPS Growth (5Y)-3.5%

Loading P/E history...

P/E Ratio Analysis

As of September 23, 2026, Pfizer Inc. (PFE) trades at a price-to-earnings ratio of 20.5x, with a stock price of $27.93 and trailing twelve-month earnings per share of $0.76.

The current P/E is roughly in line with its 5-year average of 19.8x. Over the past five years, PFE's P/E has ranged from a low of 8.0x to a high of 81.1x, placing the current valuation at the 80th percentile of its historical range.

Compared to the Healthcare sector median P/E of 24.0x, PFE is roughly in line with its sector peers. The sector includes 225 companies with P/E ratios ranging from 0.0x to 174.5x.

Relative to the broader market, PFE trades roughly in line with the S&P 500 median P/E of 25.5x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.

For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our PFE DCF Valuation Calculator →

Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.

PFE Cross-Benchmark Valuation

How does the current P/E compare to sector peers and the broader market?

vs. Healthcare
20.5vs24.0
-14%
Below Sector
vs. S&P 500
20.5vs25.5
-20%
Below Market
PEG Analysis
N/A
P/E ÷ EPS Growth
Based on -4% EPS growth (1Y)

PFE P/E vs Peers

Vaccines and plasma-derived therapies peers sorted by market cap

CompanyMarket CapP/E RatioPEG RatioEPS Growth (1Y)
JNJ logoJNJJohnson & Johnson
$648B24.41.64+91%
MRK logoMRKMerck & Co., Inc.
$373B20.70.98+8%
ABBV logoABBVAbbVie Inc.
$469B111.9--1%
LLY logoLLYEli Lilly and Company
$1.1T51.01.77+96%
BMY logoBMYBristol-Myers Squibb Company
$127B18.0-+178%
AZN logoAZNAstraZeneca PLC
$130B12.9Lowest0.59+45%
NVS logoNVSNovartis AG
$269B19.61.28+22%
AMGN logoAMGNAmgen Inc.
$221B28.89.80+88%
GILD logoGILDGilead Sciences, Inc.
$190B22.50.17Best+1684%Best
BIIB logoBIIBBiogen Inc.
$33B25.5--21%

Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.

PFE Historical P/E Data (1990–2026)

Quarterly P/E ratios calculated from closing price and TTM EPS

QuarterPeriod EndPriceTTM EPSP/E Ratiovs Avg
FY2026 Q2Jun 28 2026$24.29$0.7632.1x+28%
FY2026 Q1Mar 29 2026$27.04$1.3120.6x-18%
FY2025 Q4Dec 31 2025$24.90$1.3618.3x-27%
FY2025 Q3Sep 28 2025$23.76$1.7213.8x-45%
FY2025 Q2Jun 29 2025$24.19$1.8912.8x-49%
FY2025 Q1Mar 30 2025$25.21$1.3818.3x-27%
FY2024 Q4-$26.53$1.4118.8x-25%
FY2024 Q3Sep 29 2024$29.09$0.7439.3x+56%
FY2023 Q4Dec 31 2023$28.79$0.3581.1x+223%
FY2023 Q3Oct 01 2023$33.17$1.8218.2x-28%
FY2023 Q2Jul 02 2023$36.68$3.759.8x-61%
FY2023 Q1Apr 02 2023$40.80$5.078.0x-68%
FY2022 Q4Dec 31 2022$51.24$5.479.4x-63%
FY2022 Q3Oct 02 2022$43.76$5.198.4x-66%
FY2022 Q2Jul 03 2022$52.31$5.1110.2x-59%
FY2022 Q1Apr 03 2022$51.57$4.4011.7x-53%
FY2021 Q4Dec 31 2021$59.05$3.9015.2x-40%
FY2021 Q3Oct 03 2021$42.93$3.4612.4x-51%
FY2021 Q2Jul 04 2021$39.73$2.2917.3x-31%
FY2021 Q1Apr 04 2021$36.30$1.8919.2x-24%
FY2020 Q4-$36.81$1.6322.6x-10%
FY2020 Q3Sep 27 2020$34.17$1.4224.1x-4%
FY2020 Q2Jun 28 2020$30.37$2.5212.1x-52%
FY2020 Q1Mar 29 2020$29.29$2.7910.5x-58%
FY2019 Q4-$37.14$2.8712.9x-49%
FY2019 Q3Sep 29 2019$34.33$2.8612.0x-52%
FY2019 Q2Jun 30 2019$41.07$2.1918.8x-25%
FY2019 Q1Mar 31 2019$40.26$1.9520.6x-18%
FY2018 Q4Dec 31 2018$41.38$1.8622.2x-12%
FY2018 Q3Sep 30 2018$41.78$3.9510.6x-58%
FY2018 Q2Jul 01 2018$34.39$3.739.2x-63%
FY2018 Q1Apr 01 2018$33.64$3.599.4x-63%
FY2017 Q4Dec 31 2017$34.33$3.519.8x-61%
FY2017 Q3Oct 01 2017$33.84$1.6220.9x-17%
FY2017 Q2Jul 02 2017$31.84$1.3623.3x-7%
FY2017 Q1Apr 02 2017$32.43$1.1927.4x+9%
FY2016 Q4Dec 31 2016$30.79$1.1726.4x+5%
FY2016 Q3Oct 02 2016$32.11$1.0131.9x+27%
FY2016 Q2Jul 03 2016$33.72$1.1329.8x+18%
FY2016 Q1Apr 03 2016$28.48$1.2223.3x-7%
FY2015 Q4-$30.60$1.1127.5x+9%
FY2015 Q3Sep 27 2015$30.23$1.3322.7x-10%
FY2015 Q2Jun 28 2015$32.15$1.4122.8x-9%
FY2015 Q1Mar 29 2015$32.73$1.4422.7x-10%
FY2014 Q4Dec 31 2014$29.53$1.4220.8x-17%
FY2014 Q3Sep 28 2014$28.17$1.6217.4x-31%
FY2014 Q2Jun 29 2014$28.13$1.5917.7x-30%
FY2014 Q1Mar 30 2014$30.22$3.129.7x-61%
FY2013 Q4-$29.04$3.149.2x-63%
FY2013 Q3Sep 29 2013$27.38$3.607.6x-70%
FY2013 Q2Jun 30 2013$26.55$3.647.3x-71%
FY2013 Q1Mar 31 2013$27.36$2.0913.1x-48%
FY2012 Q4Dec 31 2012$23.77$1.9512.2x-52%
FY2012 Q3Sep 30 2012$23.56$1.2918.3x-27%
FY2012 Q2Jul 01 2012$21.80$1.3416.3x-35%
FY2012 Q1Apr 01 2012$21.47$1.2417.3x-31%
FY2011 Q4Dec 31 2011$20.51$1.2816.0x-36%
FY2011 Q3Oct 02 2011$16.76$1.4511.6x-54%
FY2011 Q2Jul 03 2011$19.67$1.0818.2x-28%
FY2011 Q1Apr 03 2011$19.32$1.0618.2x-28%
FY2010 Q4Dec 31 2010$16.60$1.0316.1x-36%
FY2010 Q3Oct 03 2010$16.29$0.7820.9x-17%
FY2010 Q2Jul 04 2010$13.40$1.1012.2x-52%
FY2010 Q1Apr 04 2010$16.19$1.1314.3x-43%
FY2009 Q4-$17.24$1.2813.5x-46%
FY2009 Q3Sep 27 2009$15.55$1.2112.9x-49%
FY2009 Q2Jun 28 2009$14.40$1.1212.9x-49%
FY2009 Q1Mar 29 2009$13.31$1.1911.2x-55%
FY2008 Q4Dec 31 2008$16.79$1.2014.0x-44%
FY2008 Q3Sep 28 2008$17.69$1.5611.3x-55%
FY2008 Q2Jun 29 2008$16.38$1.3312.3x-51%
FY2008 Q1Mar 30 2008$19.43$1.1017.7x-30%
FY2007 Q4Dec 31 2007$21.55$1.1718.4x-27%
FY2007 Q3Sep 30 2007$23.16$2.0711.2x-56%
FY2007 Q2Jul 01 2007$24.24$2.4210.0x-60%
FY2007 Q1Apr 01 2007$23.95$2.579.3x-63%
FY2006 Q4Dec 31 2006$24.55$2.659.3x-63%
FY2006 Q3Oct 01 2006$26.88$1.7215.6x-38%
FY2006 Q2Jul 02 2006$22.25$1.4815.0x-40%
FY2006 Q1Apr 02 2006$23.62$1.6214.6x-42%
FY2005 Q4Dec 31 2005$22.11$1.1020.1x-20%
FY2005 Q3Oct 02 2005$23.67$1.1021.5x-14%
FY2005 Q2Jul 03 2005$25.69$1.3219.5x-23%
FY2005 Q1Apr 03 2005$24.79$1.2320.2x-20%
FY2004 Q4Dec 31 2004$25.49$1.4917.1x-32%
FY2004 Q3Sep 26 2004$28.12$1.2023.5x-7%
FY2004 Q2Jun 27 2004$32.06$1.0530.6x+22%
FY2004 Q1Mar 28 2004$32.51$0.19173.6x+590%
FY2003 Q4Dec 31 2003$33.49$0.6551.7x+106%
FY2003 Q3Sep 28 2003$28.97$1.0328.1x+12%
FY2003 Q2Jun 29 2003$33.18$1.1229.6x+18%
FY2003 Q1Mar 30 2003$30.15$1.9115.8x-37%
FY2002 Q4-$28.98$1.4619.8x-21%
FY2002 Q3Sep 29 2002$27.09$1.3120.7x-18%
FY2002 Q2Jun 30 2002$33.18$1.2626.3x+5%
FY2002 Q1Mar 31 2002$37.67$1.2430.4x+21%
FY2001 Q4Dec 31 2001$37.78$1.2330.7x+22%
FY2001 Q3Sep 30 2001$38.01$1.1433.3x+33%
FY2001 Q2Jul 01 2001$37.97$1.0237.2x+48%
FY2001 Q1Apr 01 2001$38.82$0.9142.7x+70%
FY2000 Q4Dec 31 2000$43.61$0.8054.5x+117%
FY2000 Q3Oct 01 2000$42.60$0.7358.4x+132%
FY2000 Q2Jul 02 2000$45.50$0.6372.2x+187%
FY2000 Q1Apr 02 2000$34.66$0.5661.9x+146%
FY1999 Q4Dec 31 1999$30.75$0.5853.0x+111%
FY1999 Q3Oct 03 1999$35.37$0.5366.8x+166%
FY1999 Q2Jul 04 1999$36.61$0.7747.6x+89%
FY1999 Q1Apr 04 1999$44.10$0.8154.5x+117%
FY1998 Q4-$39.50$0.7850.7x+102%
FY1998 Q3Sep 27 1998$33.71$0.7743.8x+74%
FY1998 Q2Jun 28 1998$35.37$0.5762.1x+147%
FY1998 Q1Mar 29 1998$30.26$0.5456.1x+123%
FY1997 Q4Dec 31 1997$23.56$0.5146.2x+84%
FY1997 Q3Sep 28 1997$19.27$0.5038.4x+53%
FY1997 Q2Jun 29 1997$19.27$0.4839.9x+59%
FY1997 Q1Mar 30 1997$13.80$0.4629.8x+19%
FY1996 Q4-$13.11$0.4429.6x+18%
FY1996 Q3Sep 29 1996$12.32$0.4328.8x+14%
FY1996 Q2Jun 30 1996$11.28$0.4127.6x+10%
FY1996 Q1Mar 31 1996$10.62$0.3927.4x+9%
FY1995 Q4Dec 31 1995$9.95$0.3727.0x+7%
FY1995 Q3Oct 01 1995$8.43$0.3623.7x-6%
FY1995 Q2Jul 02 1995$7.28$0.3421.6x-14%
FY1995 Q1Apr 02 1995$6.77$0.3320.7x-18%
FY1994 Q4Dec 31 1994$6.10$0.3219.3x-23%
FY1994 Q3Oct 02 1994$5.46$0.3416.0x-36%
FY1994 Q2Jul 03 1994$4.96$0.1926.0x+3%
FY1994 Q1Apr 03 1994$4.27$0.1922.4x-11%
FY1993 Q4Dec 31 1993$5.45$0.1830.1x+20%
FY1993 Q3-$4.70$0.1045.5x+81%
FY1993 Q2Jun 30 1993$5.29$0.2322.7x-10%
FY1993 Q1Mar 31 1993$4.92$0.2123.1x-8%
FY1992 Q4-$5.73$0.1929.6x+18%
FY1992 Q3Sep 30 1992$5.90$0.1931.0x+23%
FY1992 Q2-$5.77$0.1930.3x+21%
FY1992 Q1-$5.49$0.1928.9x+15%
FY1991 Q4-$6.64$0.1934.9x+39%
FY1991 Q3Sep 30 1991$5.14$0.2322.5x-10%
FY1991 Q2Jun 30 1991$4.38$0.2220.1x-20%
FY1991 Q1Mar 31 1991$4.23$0.2120.3x-19%
FY1990 Q4Dec 31 1990$3.19$0.2016.1x-36%

Average P/E for displayed period: 25.1x

Export Data
Consensus & Technical Research Suite
Open PFE Terminal

PFE Chart Terminal

WASM

Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.

Launch Terminal

Live Breakouts Feed

LIVE

High-probability breakout stocks crossing their pivot across 5 pattern engines.

Explore Setups

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

36+ years return with dividends reinvested.

Calculate

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

PFE — Frequently Asked Questions

Quick answers to the most common questions about buying PFE stock.

What is PFE's P/E ratio?

Pfizer Inc. (PFE) trailing twelve-month P/E ratio is 20.5x, based on TTM diluted EPS of $0.76. The 5-year average P/E is 19.8x and the historical range spans 8.0x to 81.1x.

Is PFE stock overvalued or undervalued?

PFE trades at 20.5x P/E, near its 5-year average of 19.8x. The 80th percentile ranking within the 8.0x–81.1x historical range places valuation within normal bounds.

Is PFE stock expensive?

PFE is fairly valued relative to its own history. The current P/E of 20.5x is near the 5-year average of 19.8x (80th percentile of historical range).

What is PFE's historical P/E range?

Over the past 5 years, PFE's P/E ratio has ranged from 8.0x to 81.1x, with a median of 17.3x and an average of 19.8x. The current P/E of 20.5x places the stock at the 80th percentile of this range. Full historical data spans 1990–2026.

How does PFE's P/E compare to the S&P 500?

PFE trades at 20.5x P/E versus the S&P 500 median of 25.5x. The 20% discount to the market suggests lower growth expectations or perceived higher risk.

How does PFE's valuation compare to Healthcare peers?

Pfizer Inc. P/E of 20.5x compares to the Healthcare sector median of 24.0x. The discount suggests lower growth expectations, weaker margins, or higher perceived risk relative to peers. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.

What is PFE's PEG ratio?

PFE PEG ratio is N/A, based on a P/E of 20.5x and EPS growth of -3.5%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.

What is PFE's earnings yield?

PFE earnings yield is 4.87%, the inverse of its 20.5x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.

PFE P/E Ratio History (1990–2026)

Quarterly valuation multiple from closing price and trailing EPS

Current32.1x
Period Avg19.8x
Range8.0x - 81.1x
Change+67%
20 quartersApr 4, 2021 - Jun 28, 2026